Philippe Rousselot

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Medicine, Hematology, Pharmacology +4

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

Gabriel Étienne, Joëlle Guilhot, Delphine Réa et al. · Journal of Clinical Oncology · 2016 · 494 citations

Medicine, Hematology, Pharmacotherapy +15

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini et al. · New England Journal of Medicine · 2010 · 386 citations

Pharmacy, Hematology, Pharmacotherapy +6